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Abstract
Apart from complete and incomplete congenital heart block (CHB),
new cardiac manifestations related to anti-SSA/Ro antibodies have
been reported in children born to mothers bearing these
antibodies. These manifestations include transient fetal first-degree
heart block, prolongation of corrected QT (QTc) interval, sinus
bradycardia, late-onset cardiomyopathy, endocardial fibroelastosis
and cardiac malformations. Anti-SSA/Ro antibodies are not
considered pathogenic to the adult heart, but a prolongation of the
QTc interval has recently been reported in adult patients and is still
a matter of debate. Treatment of CHB is not well established and
needs to be assessed carefully. The risks and benefits of prenatal
fluorinated steroids are discussed.
Introduction
Anti-SSA/Ro antibodies have long been associated with
an increased risk of fetal congenital heart block (CHB).
Apart from complete and incomplete CHB, new cardiac
manifestations related to anti-SSA/Ro antibodies have
been reported in children born to mothers bearing these
antibodies. These manifestations include transient fetal
first-degree heart block [1], prolongation of corrected QT
(QTc) interval [2,3], sinus bradycardia [4], late-onset
cardiomyopathy [5], endocardial fibroelastosis (EFE) [6,7]
and cardiac malformation [8]. Classically, anti-SSA/Ro
antibodies have not been considered pathogenic to the
adult heart, but a prolongation of the QTc interval has
recently been reported [9].
Electrocardiogram abnormalities and 
anti-SSA/Ro antibodies
Congenital heart block
Mothers known to have anti-SSA/Ro and/or anti-SSB/La
antibodies are at risk for delivering an infant with neonatal
lupus erythematosus syndrome, which is characterized by
transient lupus dermatitis, hepatic and haematological
abnormalities, and/or isolated CHB [10]. Skin rash,
hepatitis and thrombocytopenia generally resolve without
sequel. By contrast, the heart block is permanent and
requires a pacemaker in about 66% of cases [10]. The
mortality of CHB, which is predominant in utero and in the
first months of life, is estimated at 16 to 19% [10–12].
When anti-SSA/Ro antibodies are present in sera of
mothers with connective tissue diseases (CTD), the
incidence of CHB has been reported to be 1 to 2% in live
births [4,8]. The risk of recurrence of CHB in a
subsequent child remains limited to 10 to 16% [10–12].
CHBs are usually complete but CHB of the first or second
degree can also be observed. In Buyon’s registry [13], 9
of 187 children with CHB had a first-degree block
discovered at birth through systematic electrocardiogram
(ECG). The block progressed after birth in four of these
children. Four other newborn infants had a second-degree
block; in two of them it progressed towards a third-degree
block. Such postnatal progression of CHB has been
described by others [12] and justifies performing ECGs in
newborn infants born to anti-SSA/Ro-positive mothers
even when the heart rate is normal.
Expansion of the spectrum of conducting abnormalities
In 2000, Glickstein and colleagues [14] developed pulsed
Doppler-derived PR interval measurements in fetuses, to
identify a first-degree block in utero. The method consists
of measuring the time interval from the onset of the mitral
A wave (atrial systole) to the onset of the aortic pulsed
Doppler tracing (ventricular systole) within the same left
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ventricular cardiac cycle. These authors recently validated
the accuracy of this method among physicians participa-
ting in a multi-centre prospective fetal echocardiographic
study [15]. Using the same method, Sonesson and
colleagues [1] prospectively investigated the development
of heart block in 24 unselected fetuses of anti-SSA/Ro
positive mothers. Results were compared with a large
control population of 284 healthy fetuses (data about 264
of these fetuses had previously been published [16]). A
first-degree block was detected in eight fetuses between
18 and 24 weeks of gestation. One of these eight fetuses
had progression to complete CHB despite treatment with
betamethasone, whereas another that had progressed to
a second-degree block improved to a first-degree block
after treatment with betamethasone. In the remaining six
fetuses, first-degree blocks were transient, and spontaneous
recovery occurred before or shortly after birth [1].
The same issue was investigated in a prospective multi-
centre study named PRIDE (PR interval and dexametha-
sone evaluation in CHB). This study is continuing and
assesses weekly the mechanical PR interval in pregnant
women with anti-SSA/Ro and/or anti-SSB/La antibodies.
Preliminary results [17] did not confirm the high frequency
of transient fetal first-degree CHB found by Sonesson and
colleagues [1]: only two first-degree CHBs were observed
in 66 enrolled pregnant women. Discrepancies between
these results might be related to technical differences in
measurements of PR as discussed during the Fourth
International Conference on Sex Hormones Pregnancy
and the Rheumatic Diseases (Stresa, September 2004),
and further studies are needed to clarify this point.
QTc interval prolongation in children
In the absence of CHB, a prolongation of the mean QTc
interval has been reported by Cimaz and colleagues [2] in
21 children born to anti-SSA/Ro-positive mothers in
comparison with 7 infants born to anti-SSA/Ro-negative
mothers with CTD. QTc prolongation resolved during the
first year of life [18]. Similar results were found by others
[3]. However, we have recently addressed the same issue
in a study that compared ECGs in 58 consecutive
children aged 0 to 2 months born to anti-SSA/Ro-positive
mothers with a carefully defined control group of 85
infants aged 0 to 2 months born to anti-SSA/Ro-negative
mothers with CTD. No difference was found for QTc, PR
and heart rate, and this remained true at 2 to 4 months of
life [8]. Interestingly, the mean QTc interval recorded
during the period from 2 to 4 months showed a significant
lengthening in comparison with those obtained during the
period from 0 to 2 months in both anti-SSA/Ro-positive
and anti-SSA/Ro-negative groups. In agreement with this,
in a prospective study of 4,205 healthy newborn infants,
Schwartz and colleagues [19] have shown that there was
a physiological lengthening of the QTc interval at the
second month of life. This might explain why Cimaz and
colleagues [2] found a prolongation of QTc in the anti-
SSA/Ro-positive group: at ECG recording, the median
age of this group was 90 days, compared with 7 days for
the anti-SSA/Ro-negative controls. The data are
summarized in Table 1.
QTc interval prolongation in adults
Until recently, it was supposed that CHB is due to a
peculiar vulnerability of the fetal heart between 16 and
30 weeks of gestation, and anti-SSA/Ro antibodies were
not considered pathogenic for the adult heart. In support
of this, Gordon and colleagues [20] did not find abnor-
malities of PR, QRS or QTc in ECGs of adults with anti-
SSA/Ro antibodies. Recently, Lazzerini and colleagues [9]
reported a significant prolongation of the mean QTc
interval in adult patients with anti-SSA/Ro-positive CTD in
comparison with the controls (anti-SSA/Ro-negative CTD)
[9]. However, in our study of 89 ECGs of adults with CTD,
there was no difference in QTc interval between the two
groups [21]. Thus, in agreement with Gordon and
colleagues [20], we think it unlikely that the presence of
anti-SSA/Ro antibodies is associated with prolongation of
the QTc interval in adult patients with CTD. The data are
summarized in Table 1.
Sinus bradycardia
Sinus bradycardia has recently been reported as another
ECG abnormality found in infants without CHB born to
anti-SSA/Ro-positive mothers. Brucato and colleagues [4]
reported that among 24 otherwise healthy children whose
EKGs were obtained within the first 3 days of life, 4 had
sinus bradycardia, with a mean heart rate of 84 beats/min
(range 70 to 90). Spontaneous resolution was observed
within 15 days [4]. The existence of sinus bradycardia has
been reported in two infants with anti-SSA/Ro antibodies
[22] and is supported by findings in an experimental
animal model [23] and a recent study in vitro [24].
However, as with QTc lengthening, the pathological nature
of neonatal sinus bradycardia should be established
cautiously [8,13]. A study of cardiac rate in 134 healthy
newborn infants during a 24-hour period showed that
mean lowest heart rate was 85 beats/min, and sinus
bradycardia was diagnosed in 109 healthy infants at their
lowest heart rate [25]. Additionally, as stated previously
[8], we did not find any significant difference in mean heart
rate when we compared the ECGs of 58 anti-SSA/Ro-
positive children with those of 85 anti-SSA/Ro-negative
children of the same age [8].
Myocardial abnormalities and 
anti-SSA/Ro antibodies
Late-onset dilated cardiomyopathy
Late-onset dilated cardiomyopathy developing despite the
early institution of cardiac pacing (during the first 2 weeks
of life in 15 children) has been reported in 16 infants with71
complete CHB [5]. Congestive heart failure emerged
progressively at a mean age of 11.6 months (range
2 weeks to 30 months) in 13 children. Deterioration
occurred later in life (between 3.7 and 9.3 years) in three
others. Of the 16 infants, 4 died from congestive heart
failure, 7 required cardiac transplantation, 1 was awaiting
it, and 4 exhibited recovery of the shortening fraction.
None of the 16 myocardial biopsies showed an active
inflammatory infiltrate, and immunofluorescence studies
were unrevealing. The authors found an approximately 5 to
11% risk for delayed dilated cardiomyopathy in infants
with CHB [5]. These children therefore require close
monitoring, not only of ECG and of adequate functioning
of a pacemaker, but also of ventricular function.
Endocardial fibroelastosis
The association of EFE with autoantibody-mediated CHB
was first described by Hogg in 1957 [26]. Nield and
colleagues [6] have recently reported EFE predominantly
involving the left ventricle in 13 children with complete
CHB. The date of diagnosis was prenatal in half of the
cases, and postnatal in the other half. Severe ventricular
dysfunction was present in all cases, leading to death
(n = 9) or cardiac transplantation (n = 2). Immunohisto-
chemical staining demonstrated significant deposition of
IgG and also of IgM and the presence of T cells in three
out of every four cases, suggesting that a fetal factor
might be involved in the immune process leading to EFE.
Additionally, the authors reported three cases of severe
EFE in children without CHB born to mothers with anti-
SSA/Ro antibodies. These cases have been detailed
elsewhere [7]. In agreement with this, we recently
recognized four cases that were consistent with less
severe EFE in the absence of CHB (N Costedoat-
Chalumeau, Z Amoura, E Villain, L Cohen, J-C Piette,
unpublished data). The areas of increased echogenicity
were seen predominantly in the endocardial surface of the
atrial area. In the last case, it was the hyperechogenicity
feature that prompted the cardiologists to ask for a search
for anti-SSA/Ro and anti-SSB/La antibodies in the healthy
mother. Both were positive. Because no CHB was noticed
and because the hyperechogenicity was located only in
the atria, no treatment was given. Interestingly, the child
developed a cutaneous neonatal lupus syndrome at
1 month of age. Therefore, CHB and EFE might be two
different, although frequently associated, autoantibody-
mediated manifestations of neonatal lupus erythematosus
syndrome [6].
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Table 1
Summary of the conflicting data on QTc interval in adults and in infants
Group Reference Characteristic Anti-SSA/Ro-positive group Control group P
Infants [2] No. of patients 21 7
Age (days) 90 7 NA
QTc (ms) 442 ± 35 403 ± 16 0.001
[3] No. of patients 38 7
Age (months) 65.4 1.8 NA
QTc (ms) 379 ± 26 332 ± 20 <0.0001
[8] No. of patients 58 85
Age (days) 13 ± 14 15 ± 16 0.31
QTc (ms) 397 ± 27 395 ± 25 0.57
Adults [9] No. of patients 31 26
Age (years) 41 ± 15 49 ± 13 NA
QTc (ms) 445 ± 21 419 ± 17 0.000005
[20] No. of patients 49 62
Age (years) 46 44 NS
QTc (ms) 411 ± 19 403 ± 24 0.06
[21] No. of patients 32 57
Age (years) 37 ± 11 38 ± 12 0.58
QTc (ms) 409 ± 30 409 ± 28 0.78
NA, not available; NS, not significant. Data are presented as means ± SD when available.72
Morphological heart abnormalities and 
anti-SSA/Ro antibodies
Cardiac malformations
Classically, autoantibody-mediated CHB is supposed to
affect children without major anatomic cardiac
abnormalities that would be considered causal for the
development of CHB. However, miscellaneous cardiac
structural lesions have been reported in 16 to 42% of
children with CHB born to anti-SSA/Ro-positive mothers
[10,11]. The occurrence of these lesions has never been
studied in the absence of CHB. In our series of 165
pregnancies with CTD and anti-SSA/Ro antibodies [8],
we observed two major cardiac abnormalities (associated
in one case with pulmonary hypoplasia) leading to
therapeutic abortions. One other child required neonatal
surgery for transposition of the great arteries, and one
sibling of a child with CHB had a ventricular septal defect.
In total, the rate of anatomical heart abnormalities in our
study was 4 of 141 pregnancies (2.8%). This frequency is
significantly higher than in the general population (0.54%
of all births including fetal deaths and induced abortion in
the European registry, EUROCAT [27]; P = 0.008).
Prospective studies, including data from therapeutic
abortions,  are needed for the correct evaluation of the
frequency of major anatomic heart abnormalities associated
with anti-SSA/Ro, but physicians should already be aware
of this potential risk.
Treatment of CHB
Curative treatment of CHB and prophylactic treatment to
prevent the recurrence of CHB are two major issues.
Treatment is based on fluorinated steroids (dexametha-
sone or betamethasone) that are able to cross the
placenta in an active form and may stop the immune
process involving the fetal heart. Indeed, several reports
suggest that curative treatment with fluorinated steroids is
effective for fetuses with second-degree block [1,28] or
hydropic changes associated with CHB [28]. No durable
recovery from complete CHB has yet been published.
However, fluorinated steroids may significantly improve
the survival of fetuses with complete CHB [29].
As discussed previously, the treatment of fetal incomplete
CHB may change in the future, depending on the results
of the PRIDE study. Indeed, one of the goals of this study
was to assess the efficacy of maternal dexamethasone in
reversing or preventing the progression of CHB newly
detected in utero [30]. However, it is first necessary to
establish the true prevalence of fetal first-degree CHB and
to demonstrate that first-degree CHB is a marker for more
advanced destruction of the conducting system, and then
to show that it definitely requires treatment.
Because there is no convincing evidence for the use of
steroids as preventive treatment for a pregnant woman
with a history of CHB, the prophylactic behaviour facing a
pregnant woman with previous CHB is still undetermined.
Additionally, major concerns have been raised by
paediatricians regarding the fetal safety of fluorinated
steroids, especially because of the suspected neuro-
logical toxicity of dexamethasone [31,32]. These concerns
are sustained by concordant animal studies, retrospective
data and randomized trials [32]. We have also reported a
high rate of adverse obstetric events in patients treated
with dexamethasone to prevent CHB, including spon-
taneous abortion, stillbirth, severe intrauterine growth
restriction and adrenal insufficiency/hypoplasia [32]. These
adverse events of treatment with dexamethasone are similar
to those occurring in untreated Cushing syndrome [33].
Useful guidelines for the treatment of CHB in utero have
been proposed by Buyon and colleagues [34]. We have
proposed similar guidelines for the French registry of
pregnancy with anti-SSA/Ro antibodies [35] except that, in
view of the study by Baud and colleagues [31] underlining
the risks for fetal brain associated with dexamethasone, we
prefer to use betamethasone for this purpose.
Conclusion
The spectrum of cardiac manifestations associated with
anti-SSA/Ro antibodies is undoubtedly expanding. In
addition to the classical complete and incomplete CHB,
there is progressive recognition of transient CHB, severe
late-onset cardiomyopathy and endocardial fibroelastosis.
Other possible manifestations such as sinus bradycardia
or QTc interval prolongation are currently a matter of
debate. Cardiac malformations associated with anti-
SSA/Ro antibodies are still questionable. Further studies
are needed to optimize treatment, but guidelines are
already available.
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